Economy

Markets

Industries

Insights

Reports

Events

Guilin Sanjin's H1 net profit up 13.34%

By Song Jingli (chinadaily.com.cn)
Updated: 2009-07-28 11:17

Guilin Sanjin Pharmaceutical Co, a traditional Chinese medicine maker, saw strong earnings this year, according to its interim report, which the company released yesterday.

Related readings:  Investors flock to buy Guilin Sanjin shares  Guilin Sanjin says IPO price fixed at 19.8 yuan per share  Guilin Sanjin sets the China IPO ball rolling  China stock regulator approves new IPO

Guilin Sanjin, the first company to raise money from Shenzhen Stock Exchange market via an initial public offering (IPO) after the ban on new share issues was lifted last month, posted a net profit of about 159.98 million yuan ($23.42 million) in the first half, up 13.34 percent year-on-year.

The company reaped a revenue of 479.85 million yuan, up nine percent over the same period a year earlier.

In the first six months this year, the company's per-share earnings rose 11.43 percent to 0.39 yuan and its return on equity ratio reached 20.86 percent, up 4.48 percent year-on-year.